Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 2/20 | 0.34 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659036 | 1.00 | CXCL8 (0.40) | CXCL8ALDH1A1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL1067362 | 1.00 | CXCL8 (0.40) | CXCL8ALDH1A1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL1064282 | 0.91 | CARM1 (0.36) | ALDH1A1NPSR1HTTMCL1KMT2A | |
| SCHEMBL1066409 | 0.91 | CARM1 (0.36) | ALDH1A1NPSR1HTTMCL1KMT2A | |
| SCHEMBL2656465 | 0.90 | CXCL8 (0.38) | CXCL8ALDH1A1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL2657654 | 0.90 | CXCL8 (0.38) | CXCL8ALDH1A1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL2656735 | 0.90 | CXCL8 (0.38) | CXCL8ALDH1A1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL2657867 | 0.90 | CXCL8 (0.38) | CXCL8ALDH1A1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL1067666 | 0.90 | CXCL8 (0.38) | CXCL8ALDH1A1NPSR1CYP1A2CYP3A4 | |
| SCHEMBL1067667 | 0.90 | CXCL8 (0.38) | CXCL8ALDH1A1NPSR1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2938609-A1 | PROCESS FOR THE PREPARATION OF 1-([1,3]DIOXOLAN-4-YLMETHYL)-1H-PYRAZOL-3-YLAMINE | Hua Medicine (CN) | 2015-11-04 | — | — | EP | claimed |
| WO-2014102164-A1 | PROCESS FOR THE PREPARATION OF 1-([1,3]DIOXOLAN-4-YLMETHYL)-1H-PYRAZOL-3-YLAMINE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-03 | — | — | WO | claimed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | claimed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | claimed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | claimed |
| US-11992477-B2 | Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2024-05-28 | — | — | US | disclosed |
| CN-117940419-A | Prodrugs of pyrrolidone derivatives as glucokinase activators | 华领医药技术（上海）有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11963947-B2 | Pharmaceutical combination, composition and compound preparation comprising glucokinase activator and DPP-IV inhibitor, and preparation method and use thereof | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2024-04-23 | — | — | US | disclosed |
| CN-114712488-B | Pharmaceutical compositions of dorzagliptin and glucagon-like peptide-1 analogs | 华领医药技术（上海）有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230346748-A1 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION CONTAINING GLUCOKINASE ACTIVATOR AND K-ATP CHANNEL BLOCKER, PREPARATION METHOD THEREFOR AND USE THEREOF | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230322738-A1 | PRODRUG OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATOR | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-11666556-B2 | Pharmaceutical combination, composition and compound preparation containing glucokinase activator and K-ATP channel blocker, preparation method therefor and use thereof | HUA MEDICINE (SHANGHAI) LIMITED (CN) | 2023-06-06 | — | — | US | disclosed |
| WO-2014102164-A1 | PROCESS FOR THE PREPARATION OF 1-([1,3]DIOXOLAN-4-YLMETHYL)-1H-PYRAZOL-3-YLAMINE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014102164-A1 | PROCESS FOR THE PREPARATION OF 1-([1,3]DIOXOLAN-4-YLMETHYL)-1H-PYRAZOL-3-YLAMINE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-03 | — | — | WO | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| EP-2274297-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666556-B2 | Pharmaceutical combination, composition and compound preparation containing glucokinase activator and K-ATP channel blocker, preparation method therefor and use thereof | SLC5A1, KCNJ11, SLC5A2 | CXCL8 1705/4885ALDH1A1 2036/4885NPSR1 2562/4885 |
| US-20230346748-A1 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION CONTAINING GLUCOKINASE ACTIVATOR AND K-ATP CHANNEL BLOCKER, PREPARATION METHOD THEREFOR AND USE THEREOF | SLC5A1, KCNJ11, SLC5A2 | CXCL8 1705/4885ALDH1A1 2036/4885NPSR1 2562/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | CXCL8 3474/4885ALDH1A1 1129/4885NPSR1 3628/4885 |
| US-20230322738-A1 | PRODRUG OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATOR | GCK, GCKR, SLC5A1 | CXCL8 4038/4885ALDH1A1 941/4885NPSR1 2512/4885 |
| US-11963947-B2 | Pharmaceutical combination, composition and compound preparation comprising glucokinase activator and DPP-IV inhibitor, and preparation method and use thereof | DPP4, DPP7, DPP8 | CXCL8 2823/4885ALDH1A1 1645/4885NPSR1 3866/4885 |
| US-11992477-B2 | Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof | SLC5A2, SLC5A1, GCK | CXCL8 2542/4885ALDH1A1 2045/4885NPSR1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.